An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) announced it will report its fourth quarter and year-end 2021 financial results on March 3, 2022, after U.S. market close. A conference call and live webcast will follow at 4:30 p.m. ET, including a Q&A session. Participants can join via phone or through the Evolus website. A replay of the call will be available after completion. Evolus, known for its neurotoxin Jeuveau®, focuses on redefining the aesthetic market with innovative customer-centric products.
Positive
None.
Negative
None.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022, after the U.S. financial markets close.
Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Investor/Media Contact:
David K. Erickson, Evolus, Inc. Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Source: Evolus
FAQ
When will Evolus report its fourth quarter and year-end 2021 financial results?
Evolus will report its financial results on March 3, 2022, after the U.S. markets close.
What time is the Evolus conference call scheduled for?
The Evolus conference call is scheduled for 4:30 p.m. ET on March 3, 2022.
How can I access the Evolus conference call?
You can access the Evolus conference call by dialing (877) 407-6184 for the U.S. or (201) 389-0877 for international participants, or you can join via the Evolus website.
Is there a replay available for the Evolus conference call?
Yes, a telephonic replay will be available by dialing (877) 660-6853 for the U.S. or (201) 612-7415 internationally.
What product is Evolus known for?
Evolus is known for its neurotoxin product, Jeuveau®, which is dedicated exclusively to aesthetics.
